Global RNAi Technology 麻豆原创 Research Report 2023

Publication ID:

PB510230397

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

RNA interference is a relatively new concept in the field of medicine. It is a process in which the ribonucleic acid inhibits translation or gene expression by converting single-stranded mRNA to double stranded RNA, thereby neutralizing the target nucleic acids.
The global RNAi Technology market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Technology market research.
As an important force driving a new round of scientific and technological revolution, artificial intelligence has been of national strategic importance. Many governments introduces polices and increase capital investment to support AI companies. The Digital Europe plan adopted by the European Union will allocate 鈧�9.2 billion on high-tech investments, such as supercomputing, artificial intelligence, and network security. In order to maintain its leading position, the United States will increase its investment in artificial intelligence research and development in non-defense fields, from US$1.6 billion to US$1.7 billion in 2022. According to the latest data released by IDC, global artificial intelligence revenue was US$432.8 billion in 2022, a year-on-year increase of 19.97%, including software, hardware and services.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global RNAi Technology market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics
Segment by Type
Cancer
Liver Disorders
Respiratory Disorders
Neurological Disorders
Autoimmune Disorders
Others
Segment by Application
Drug Discovery & Development
Therapeutics
Drug Delivery
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The RNAi Technology report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global RNAi Technology 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cancer
1.2.3 Liver Disorders
1.2.4 Respiratory Disorders
1.2.5 Neurological Disorders
1.2.6 Autoimmune Disorders
1.2.7 Others
1.3 麻豆原创 by Application
1.3.1 Global RNAi Technology 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Drug Discovery & Development
1.3.3 Therapeutics
1.3.4 Drug Delivery
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNAi Technology 麻豆原创 Perspective (2018-2029)
2.2 RNAi Technology Growth Trends by Region
2.2.1 Global RNAi Technology 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 RNAi Technology Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 RNAi Technology Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 RNAi Technology 麻豆原创 Dynamics
2.3.1 RNAi Technology Industry Trends
2.3.2 RNAi Technology 麻豆原创 Drivers
2.3.3 RNAi Technology 麻豆原创 Challenges
2.3.4 RNAi Technology 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNAi Technology Players by Revenue
3.1.1 Global Top RNAi Technology Players by Revenue (2018-2023)
3.1.2 Global RNAi Technology Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global RNAi Technology 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNAi Technology Revenue
3.4 Global RNAi Technology 麻豆原创 Concentration Ratio
3.4.1 Global RNAi Technology 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNAi Technology Revenue in 2022
3.5 RNAi Technology Key Players Head office and Area Served
3.6 Key Players RNAi Technology Product Solution and Service
3.7 Date of Enter into RNAi Technology 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 RNAi Technology Breakdown Data by Type
4.1 Global RNAi Technology Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global RNAi Technology Forecasted 麻豆原创 Size by Type (2024-2029)
5 RNAi Technology Breakdown Data by Application
5.1 Global RNAi Technology Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global RNAi Technology Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America RNAi Technology 麻豆原创 Size (2018-2029)
6.2 North America RNAi Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America RNAi Technology 麻豆原创 Size by Country (2018-2023)
6.4 North America RNAi Technology 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNAi Technology 麻豆原创 Size (2018-2029)
7.2 Europe RNAi Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe RNAi Technology 麻豆原创 Size by Country (2018-2023)
7.4 Europe RNAi Technology 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNAi Technology 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific RNAi Technology 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific RNAi Technology 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific RNAi Technology 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNAi Technology 麻豆原创 Size (2018-2029)
9.2 Latin America RNAi Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America RNAi Technology 麻豆原创 Size by Country (2018-2023)
9.4 Latin America RNAi Technology 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNAi Technology 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa RNAi Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa RNAi Technology 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa RNAi Technology 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Detail
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals RNAi Technology Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in RNAi Technology Business (2018-2023)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Dicerna Pharmaceuticals, Inc.
11.2.1 Dicerna Pharmaceuticals, Inc. Company Detail
11.2.2 Dicerna Pharmaceuticals, Inc. Business Overview
11.2.3 Dicerna Pharmaceuticals, Inc. RNAi Technology Introduction
11.2.4 Dicerna Pharmaceuticals, Inc. Revenue in RNAi Technology Business (2018-2023)
11.2.5 Dicerna Pharmaceuticals, Inc. Recent Development
11.3 Arrowhead Pharmaceuticals, Inc.
11.3.1 Arrowhead Pharmaceuticals, Inc. Company Detail
11.3.2 Arrowhead Pharmaceuticals, Inc. Business Overview
11.3.3 Arrowhead Pharmaceuticals, Inc. RNAi Technology Introduction
11.3.4 Arrowhead Pharmaceuticals, Inc. Revenue in RNAi Technology Business (2018-2023)
11.3.5 Arrowhead Pharmaceuticals, Inc. Recent Development
11.4 Ionis Pharmaceuticals, Inc.
11.4.1 Ionis Pharmaceuticals, Inc. Company Detail
11.4.2 Ionis Pharmaceuticals, Inc. Business Overview
11.4.3 Ionis Pharmaceuticals, Inc. RNAi Technology Introduction
11.4.4 Ionis Pharmaceuticals, Inc. Revenue in RNAi Technology Business (2018-2023)
11.4.5 Ionis Pharmaceuticals, Inc. Recent Development
11.5 Quark Pharmaceuticals, Inc.
11.5.1 Quark Pharmaceuticals, Inc. Company Detail
11.5.2 Quark Pharmaceuticals, Inc. Business Overview
11.5.3 Quark Pharmaceuticals, Inc. RNAi Technology Introduction
11.5.4 Quark Pharmaceuticals, Inc. Revenue in RNAi Technology Business (2018-2023)
11.5.5 Quark Pharmaceuticals, Inc. Recent Development
11.6 Arbutus Biopharma
11.6.1 Arbutus Biopharma Company Detail
11.6.2 Arbutus Biopharma Business Overview
11.6.3 Arbutus Biopharma RNAi Technology Introduction
11.6.4 Arbutus Biopharma Revenue in RNAi Technology Business (2018-2023)
11.6.5 Arbutus Biopharma Recent Development
11.7 Benitec Biopharma
11.7.1 Benitec Biopharma Company Detail
11.7.2 Benitec Biopharma Business Overview
11.7.3 Benitec Biopharma RNAi Technology Introduction
11.7.4 Benitec Biopharma Revenue in RNAi Technology Business (2018-2023)
11.7.5 Benitec Biopharma Recent Development
11.8 Calando
11.8.1 Calando Company Detail
11.8.2 Calando Business Overview
11.8.3 Calando RNAi Technology Introduction
11.8.4 Calando Revenue in RNAi Technology Business (2018-2023)
11.8.5 Calando Recent Development
11.9 Silence Therapeutics
11.9.1 Silence Therapeutics Company Detail
11.9.2 Silence Therapeutics Business Overview
11.9.3 Silence Therapeutics RNAi Technology Introduction
11.9.4 Silence Therapeutics Revenue in RNAi Technology Business (2018-2023)
11.9.5 Silence Therapeutics Recent Development
11.10 Gotham Therapeutics
11.10.1 Gotham Therapeutics Company Detail
11.10.2 Gotham Therapeutics Business Overview
11.10.3 Gotham Therapeutics RNAi Technology Introduction
11.10.4 Gotham Therapeutics Revenue in RNAi Technology Business (2018-2023)
11.10.5 Gotham Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.